GT BIOPHARMA, INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
GT BIOPHARMA, INC. (GTBP) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -4.00% for the 12-month period ending 2013-12-31, per its 10-K filed 2015-01-08.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2015-01-08
- GT BIOPHARMA, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2013 was -4.00%.
- GT BIOPHARMA, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2012 was -4.00%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month |
|---|---|
| 2013-12-31 | -4.00% 10-K · filed 2015-01-08 |
| 2012-12-31 | -4.00% 10-K · filed 2015-01-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |